Loading…
Adlai Nortye Ltd. is projected to rise to $17.33 by 2027, a +76% move from its current price of $9.87. ANL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $9.32 | $9.88 | $10.47 | +0.08% |
| Jul 15 | $9.10 | $9.89 | $10.74 | +0.16% |
| Jul 16 | $8.94 | $9.89 | $10.95 | +0.24% |
| Jul 17 | $8.81 | $9.90 | $11.13 | +0.32% |
| Jul 18 | $8.70 | $9.91 | $11.29 | +0.40% |
| Jul 19 | $8.60 | $9.92 | $11.44 | +0.48% |
| Jul 20 | $8.50 | $9.93 | $11.58 | +0.56% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.50 | $9.93 | $11.58 | +0.56% |
| Week 2 | $8.02 | $9.98 | $12.42 | +1.13% |
| Week 3 | $7.68 | $10.04 | $13.12 | +1.70% |
| Week 4 | $7.41 | $10.09 | $13.75 | +2.27% |
| Week 5 | $7.18 | $10.15 | $14.34 | +2.85% |
| Week 6 | $6.99 | $10.21 | $14.91 | +3.43% |
| Week 7 | $6.82 | $10.27 | $15.45 | +4.01% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Adlai Nortye Ltd. (ANL) is a healthcare company in the clinical stage that researches and develops pharmaceutical products. Its product pipeline includes AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer.
The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed to deliver potent anti-tumor activity with an improved therapeutic window; and AN8025, a tri-specific antibody fusion protein which is in phase Ia clinical trial to treat advanced tumors. In addition, it develops AN4005, a small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction which is in phase 1b clinical trial to activate cancer immunity. Further, the company is involved in technology transfer and consulting services business.
Adlai Nortye Ltd. was founded in 2004 and is headquartered in North Brunswick, New Jersey.
Adlai Nortye Ltd. is a clinical-stage healthcare company focused on developing pharmaceutical products. The stock ANL is currently trading with a price of $9.87 and a market cap of $635.61M, ranking 2855 by size.
The near-term forecast for 2026 shows a range and a current-price-aligned average, illustrating potential price variability around the present level.
A major floor 34.5% below — a decisive break under it would weaken the trend.
The nearest floor, 3.9% below — buyers have tended to step in here.
The nearest ceiling, 21.9% above — a clean break opens room to run.
A major ceiling 68.2% above — clearing it would confirm fresh momentum.
Key ANL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ANL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.48 | Sell | $10.32 | Sell |
| MA 10 | $10.54 | Sell | $10.44 | Sell |
| MA 20 | $10.49 | Sell | $10.61 | Sell |
| MA 50 | $11.65 | Sell | $10.93 | Sell |
| MA 100 | $10.85 | Sell | $10.07 | Sell |
| MA 200 | $6.71 | Buy | $7.99 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.48 | Neutral |
| Stoch RSI (14) | 28.92 | Neutral |
| CCI (20) | -94.67 | Neutral |
| Williams %R (14) | -81.09 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -6.89 | Sell |
| Bollinger %B (20,2) | 0.20 | Neutral |
| Stochastic %K (14) | 18.91 | Buy |
| TRIX (15) | -0.42 | Sell |
| Awesome (5,34) | -0.29 | Sell |
| Ultimate (7,14,28) | 40.18 | Neutral |
| Momentum (10) | -0.29 | Sell |
| Aroon Osc (25) | -8.00 | Sell |
| Hull MA (9) | 10.30 | Sell |
| ADX (14) | 10.15 | Neutral |
| ATR (14) | 0.62 | Info |
The 30-day technical picture shows a bullish bias with RSI(14) at 40, and price action influenced by key moving averages. The SMA50 is $11.65 and the SMA200 is $6.71, with a defined support at $9.49 and resistance at $12.03. The 30-day price range runs from $6.71 to $14.51, highlighting near-term upside potential if the price breaks above resistance.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.38 | $9.87 | $18.03 | 0% | Neutral | |
| $12.57 | $17.33 | $25.82 | +76% | Bullish | |
| $15.50 | $22.70 | $36.04 | +130% | Bullish | |
| $14.43 | $22.26 | $37.10 | +125% | Bullish | |
| $14.52 | $23.48 | $40.74 | +138% | Bullish | |
| $14.99 | $25.34 | $45.51 | +157% | Bullish | |
| $13.11 | $23.12 | $42.81 | +134% | Bullish | |
| $18.61 | $34.17 | $65.05 | +246% | Bullish | |
| $23.98 | $45.81 | $89.41 | +364% | Bullish | |
| $22.91 | $45.48 | $90.83 | +361% | Bullish | |
| $29.93 | $66.50 | $145.98 | +574% | Bullish | |
| $55.58 | $123.52 | $284.09 | +11.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.38 | $9.87 | $12.69 | +0.00% |
| August 2026 | $8.96 | $10.85 | $13.67 | +9.88% |
| September 2026 | $8.65 | $10.62 | $13.67 | -2.08% |
| October 2026 | $9.22 | $11.47 | $15.02 | +7.97% |
| November 2026 | $10.36 | $13.01 | $17.29 | +13.46% |
| December 2026 | $10.56 | $13.39 | $18.03 | +2.94% |
Click any year to see its month-by-month ANL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Adlai Nortye Ltd.'s 2026 outlook centres on $9.87, within a $1.38 to $18.03 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ANL could reach as high as $25.82, with a base case around $17.33 and support toward $12.57 — roughly +76% from $9.87. Buyers look set to stay in control over this stretch.
Expect ANL to range from $15.50 to $36.04 through 2028. The $22.70 average target implies a +130% move from current prices. That is up +31% on the projected 2027 average. Momentum favours further upside here.
The ANL price prediction for 2029 points to an average of $22.26 (low $14.43, high $37.10) — a potential gain of +125% on today's $9.87. Buyers look set to stay in control over this stretch.
In 2030, ANL is projected to trade between $14.52 and $40.74, averaging $23.48 — a potential gain of +138% from today's $9.87. That is up +5% on the projected 2029 average. Momentum favours further upside here.
Adlai Nortye Ltd.'s 2031 outlook centres on $25.34, within a $14.99 to $45.51 range. That is up +8% on the projected 2030 average. That marks a +157% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ANL could reach as high as $42.81, with a base case around $23.12 and support toward $13.11 — roughly +134% from $9.87. Momentum favours further upside here.
Expect ANL to range from $18.61 to $65.05 through 2033. The $34.17 average target implies a +246% move from current prices. That is up +48% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ANL price prediction for 2034 points to an average of $45.81 (low $23.98, high $89.41) — a potential gain of +364% on today's $9.87. Momentum favours further upside here.
In 2035, ANL is projected to trade between $22.91 and $90.83, averaging $45.48 — a potential gain of +361% from today's $9.87. That is -1% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Adlai Nortye Ltd.'s 2040 outlook centres on $66.50, within a $29.93 to $145.98 range. That is up +46% on the projected 2035 average. That marks a +574% change versus current levels. Momentum favours further upside here.
By 2050, ANL could reach as high as $284.09, with a base case around $123.52 and support toward $55.58 — roughly +11.5x from $9.87. Buyers look set to stay in control over this stretch.
Investing $1,000 in ANL today (≈ 101.317123 ANL) could be worth
$12,514.45
+$11,514.45 (+1151%) by 2050 · US Dollar
Based on the average projected ANL price of $123.52 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ANLwould be worth at today's price.
$1,000 invested in ANL on Jul 10, 2025 (≈ 662.25166 ANL) would be worth
$6,536.42
+$5,536.42 (+553.6%) today · 6.54× · US Dollar
Based on a ANL entry price of $1.51 vs. today's $9.87.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.49 | $1,040.04 | +4.0% |
| 1 month ago | $10.47 | $942.69 | -5.7% |
| 3 months ago | $11.16 | $884.41 | -11.6% |
| 6 months ago | $1.59 | $6,207.55 | +520.8% |
| 1 year ago | $1.51 | $6,536.42 | +553.6% |
| All time (2.8y) ago | $15 | $658 | -34.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ANL forecast.
Our base-case forecast reaches $20.00 around 2028.
Implied market cap at $20.00: $1.17B
Longer-term forecasts project meaningful upside with a bullish sentiment across multiple years. For 2026 the average price is $9.87 with a max of $18.03 and a min of $1.38. By 2027 the average target rises to $17.34 with a 75.7% ROI and a bullish stance, and it continues to trend higher in subsequent years.
In 2028 the average target is $22.76 (ROI 130.6%), in 2029 $22.21 (ROI 125.1%), and in 2030 $23.50 (ROI 138.1%) with a max of $40.79. The forecast extends to 2031 with an average of $25.39 (ROI 157.3%), 2032 $23.00 (ROI 133.1%), 2033 $34.33 (ROI 247.8%), 2034 $45.97 (ROI 365.8%), and 2035 $45.21 (ROI 358.1%). The long-range outlook shows substantial upside: 2040’s average is $66.70 (ROI 575.8%) and 2050’s average is $123.08 (ROI 1147.1%), with corresponding maxima of $146.43 and $283.09 respectively.
These are estimates, not guarantees, and carry inherent uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $23.50, a min of $14.53, and a max of $40.79, with a forecasted ROI of 138.1% and a bullish sentiment.
The long-term outlook is bullish, with rising average targets and high potential ROI by 2030, 2040, and 2050 (e.g., 2040 avg $66.70 and 2050 avg $123.08 with ROIs of 575.8% and 1147.1%, respectively). These are estimates and not guarantees.
Yes—the 2030 max forecast is $40.79, with a 2030 average of $23.50 and a min of $14.53.
The 2040 forecast shows an average price of $66.70, a min of $30.02, and a max of $146.43, with a ROI of 575.8% and bullish sentiment.
The 2050 forecast shows an average price of $123.08, a min of $55.39, and a max of $283.09, with a ROI of 1147.1% and bullish sentiment.
Adlai Nortye Ltd. Community Discussion
0Share your Adlai Nortye Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.